3:22 AM
 | 
Jul 06, 2018
 |  BioCentury  |  Finance

Dynacure’s quick transfer

Born via Kurma’s industry-tied tech transfer model, Dynacure heads for the clinic

A new €47 million ($54.7 million) round will allow Dynacure S.A.S. to begin clinical testing of its lead program to treat centronuclear myopathy (CNM) less than three years after its inception. The round is also the biggest announced yet by a start-up formed via Kurma Partners S.A.’s company creation model, which the French firm revealed in late 2016.

Andera Partners (formerly Edmond de Rothschild Investment Partners) led the new round, which is Dynacure’s first equity installment beyond its initial €2 million ($2.3 million) in seed funding from Kurma. Also participating were existing investor Bpifrance and new investors Pontifax and IdInvest Partners, as well as Kurma.

Alongside Dynacure’s partner Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and tech transfer office SATT Conectus Alsace, Kurma founded Dynacure in 2016 to develop an antisense...

Read the full 620 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >